Corrigendum| Volume 25, 100196, March 2023

Download started.


Corrigendum to “Harmonization of breast cancer radiotherapy treatment planning in the Netherlands” [Tech. Innov. Patient Support Radiat. Oncol. 19 (2021) 26–32]

Open AccessPublished:January 07, 2023DOI:
      The authors regret that the following Patient Consent Statement was missing from the above article:
      Patient Consent
      The research was conducted on anonymized patient data according to Dutch data protection and privacy legislation.
      The authors would like to apologise for any inconvenience caused.

      Linked Article

      • Harmonization of breast cancer radiotherapy treatment planning in the Netherlands
        Technical Innovations and Patient Support in Radiation Oncology Vol. 19
        • Preview
          Postoperative breast cancer radiotherapy (RT) reduces the risk of local recurrence with a factor of 3–4 [1]. In The Netherlands the standard schedule for breast radiotherapy has been 15 fractions of 2.67 Gy since 2013, based on 10-year follow-up results of the START B trial [2]. When designing an RT plan, a continuous trade off between optimal dose to the target versus optimal sparing of organs at risk (OAR) needs to be made. As the relationship between dose-volume parameters, local control and side-effects is not very clear, and because the acceptance of a local recurrence risk and side effects differ per physician and per patient, a wide practice variation exists in the trade-offs made.
        • Full-Text
        • PDF
        Open Access